| content | |||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
LSM-775
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C20H23N3O2 |
| Mol. mass | 337.43 g/mol |
| Synonyms | LSM-775, N-Morpholinyllysergamide |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | hepatic |
| Half life | ? |
| Excretion | renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
N-Morpholinyllysergamide (LSM-775) is a derivative of ergine. It is reported to have some LSD-like effects at doses ranging from 75 to 700 micrograms. LSM-775 is said to produce dream like states similar to DXM. Its visual component is like that of LSD, but it is said to be less intense and not as pronounced as LSD.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||
